It usually arrives as a letter. Sometimes it’s addressed to you by name, sometimes to the household. It mentions stroke, which is the one word that stops most people over 50 mid-recycling. It names a nearby church, community center, or hotel ballroom and a date a few weeks out. It offers a package of painless ultrasound screenings for around $150 to $190, and it often has a discount code.
That’s Life Line Screening, and if you’re reading this, you’ve probably got the letter on the kitchen counter and a nagging question: should I go?
It’s a fair question, and a surprisingly hard one to answer from the internet. Most of what ranks for it is either Life Line’s own marketing, aggregated customer reviews (“the staff were lovely”), or coupon sites. The staff probably are lovely. That’s not the question. The question is whether these specific tests, done on people who feel fine, are likely to help you, and that’s something the evidence can actually answer. It just answers it differently for each test.
So we went test by test: what the US Preventive Services Task Force (USPSTF) says, what randomized trials show, what Life Line’s own published data reveals about how often these conditions turn up, and what a major carotid trial published in late 2025 changes.
TL;DR
- One test is genuinely well-supported: the abdominal aortic aneurysm (AAA) ultrasound, for men aged 65 to 75 who have ever smoked (USPSTF grade B). Screening cut AAA deaths by about 35% in trials. But Medicare covers this test free, once, with a referral.
- The headline test, carotid artery ultrasound, is one the USPSTF recommends against (grade D) for people without stroke symptoms. When severe narrowing is rare, most positive results are false alarms, and follow-up procedures can themselves cause strokes.
- The peripheral artery disease (ankle-brachial index) and atrial fibrillation (one-time EKG) screens have insufficient evidence (grade I). The ABI misses 80% to 85% of disease in the best available study, so a normal result is weak reassurance.
- The bone density screen isn’t DXA, the reference test. Medicare covers DXA every two years for eligible people.
- The four-test Heart & Stroke package was listed at $186 in October 2026, with mailer and partner discounts often bringing it to about $129 to $159. It’s self-pay and HSA/FSA eligible.
- New in 2025: the CREST-2 trial found that for confirmed severe carotid narrowing, stenting plus intensive medical therapy reduced stroke over four years. That makes a severe finding more actionable than before, but it doesn’t fix the false-positive problem, and the USPSTF hasn’t re-reviewed screening since.
Quick Verdict
- Reasonable to go: a man aged 65 to 75 who has ever smoked, has never had an aortic ultrasound, and isn’t going to get one through a doctor. Or anyone with a parent or sibling who had an aortic aneurysm.
- Probably skip it: anyone with a primary care doctor and insurance or Medicare. You can get the evidence-backed parts (AAA screening if eligible, blood pressure, cholesterol, A1C, DXA) covered, usually at no cost, and skip the parts guideline bodies advise against.
- Definitely don’t use it instead of a doctor: if you’ve had symptoms like sudden one-sided weakness, numbness, slurred speech, temporary vision loss in one eye, or leg pain when walking that eases with rest. Those need a real medical evaluation, not a screening event. Sudden symptoms need 911.
- If you’ve already been and something was flagged: jump to what to do with an abnormal result.
What Life Line Screening Actually Is
Life Line Screening is a privately held company founded in Florida in 1993, now headquartered in Independence, Ohio. It runs mobile, community-based screening events for adults (mainly 50 and older) in churches, community centers, and similar venues across the US. It says it has screened more than 11 million people. Scans are done by trained technicians, not physicians, and the company says its AFib, AAA, and carotid results are reviewed by licensed, board-certified physicians.
It’s a real company doing real tests on real equipment. Its own screening data, from more than 3.6 million self-referred Americans, was analyzed by outside researchers and published in the Journal of the American College of Cardiology in 2013. Whether it’s a scam isn’t the question. The question is whether its core tests should be done on people without symptoms. On that, the company and the major guideline bodies disagree.
What it costs in 2026
When we checked Life Line’s screening services page in October 2026:
| Package | Listed price | What’s in it |
|---|---|---|
| Heart & Stroke Risk | $186 | Carotid artery, abdominal aortic aneurysm, peripheral arterial disease, atrial fibrillation (4 screenings) |
| Chronic Disease Risk | $285 | The above plus a finger-stick blood panel and a chronic disease risk assessment (10 screenings) |
| Men’s & Women’s Health | $384 | Adds liver and kidney function, A1C, hormone levels (15 screenings) |
| Complete Preventative Care Suite | $483 | Adds a mid-year monitoring blood panel (19 screenings) |
| OneLife Membership | $197/year | Annual cardiovascular and stroke screening, results consultation, bone density and cortisol screening included |
Prices from lifelinescreening.com/screening-services, accessed October 2026. Prices shown elsewhere on Life Line’s site weren’t fully consistent with this page when we checked, and mailers routinely carry promotional codes. Promotions and partner discounts (through farm bureaus, realtor associations, and other member groups) have put the four-test package at around $129 to $159. Confirm the price for your event directly.
All packages are self-pay. They’re HSA/FSA eligible, and Life Line states in partner materials that it doesn’t participate in Medicare, so Medicare won’t reimburse you.
The Evidence, Test by Test
Here’s the whole picture before the detail. Grades are from the USPSTF, the independent federal panel whose A and B ratings determine what insurers must cover at no cost.
| Life Line test | Method | USPSTF grade (adults without symptoms) | Free elsewhere? |
|---|---|---|---|
| Abdominal aortic aneurysm | Ultrasound of the abdomen | B for men 65–75 who ever smoked · C for men 65–75 who never smoked · I for women 65–75 who ever smoked or have family history · D for women who never smoked with no family history (2019) | Yes: Medicare covers once for at-risk people with a referral |
| Carotid artery disease | Ultrasound of the neck arteries | D (recommend against) (2014, reaffirmed 2021) | Not recommended for screening anyway |
| Peripheral arterial disease | Ankle-brachial index (blood pressure at ankles vs. arms) | I (insufficient evidence) (2018) | Your doctor can do it in minutes if you have symptoms or risk factors |
| Atrial fibrillation | Limb-lead EKG | I (insufficient evidence) (2022) | A routine pulse check at any visit; many smartwatches also check |
| Bone density | Ultrasound at the heel or shin (not DXA) | Not applicable to ultrasound. DXA screening is B for women 65+ and at-risk postmenopausal women under 65; I for men (2025) | Yes: Medicare covers DXA every 24 months for eligible people |
| Blood panels (lipids, glucose, A1C, etc.) | Finger-stick | Statin-decision lipid testing and diabetes screening are part of grade B recommendations | Yes: covered preventive labs through your doctor |
Now the detail, starting with the test that’s actually doing the heavy lifting.
1. Abdominal aortic aneurysm (AAA): the one with strong evidence
The aorta is the body’s main artery, and in some people its abdominal section slowly balloons. An aneurysm usually causes no symptoms until it ruptures, and a rupture is frequently fatal. That’s the kind of condition screening is good for: common enough in a defined group, silent, easy to see on a cheap ultrasound, and treatable before disaster.
The evidence matches. In the USPSTF’s 2019 review, pooled from four large trials mostly of men 65 and older:
- AAA-related deaths fell about 35% in men invited to screening.
- About 305 men needed to be invited to screening to prevent one AAA death.
- Rupture fell, and screening 1,000 men prevented about two emergency operations.
Two honest caveats. First, screening didn’t reduce deaths from all causes. Second, screened men had about 40% more aneurysm operations, mostly planned ones. Most screen-detected aneurysms (90% or more) are between 3.0 and 5.5 cm, below the usual repair threshold of 5.5 cm, so most people found to have one get periodic ultrasounds rather than surgery.
The risk is concentrated in a specific group. Life Line’s own dataset found an aneurysm in just 0.9% of the 3.6 million people screened. In screening trials of older men, prevalence ran 4.0% to 7.6%; in one trial, it was 1.3% in women versus 7.6% in men. Smoking is the dominant risk factor. That’s why the USPSTF:
- recommends one-time screening (grade B) for men 65 to 75 who have ever smoked;
- suggests clinicians selectively offer it (grade C) to men 65 to 75 who never smoked;
- finds insufficient evidence (I) for women 65 to 75 who have smoked or have a family history; and
- recommends against it (D) for women who have never smoked and have no family history.
The catch: if you’re on Medicare and in the at-risk group, Part B covers a one-time AAA ultrasound with a referral, and you pay nothing if the provider accepts assignment. Medicare defines at-risk as a family history of AAA, or being a man aged 65 to 75 who has smoked at least 100 cigarettes. So for the person this test helps most, the same scan is often free.
Where Life Line’s version can make sense: a man in that group who has no regular doctor, or whose doctor has never brought it up. A one-time scan that catches an aneurysm in a 70-year-old former smoker is the clearest example of screening done right, wherever it happens.
2. Carotid artery ultrasound: the headline test, and the one guidelines say to skip
This is the test that sells the package. The mailer talks about stroke, and the carotid arteries in your neck supply blood to your brain. Plaque narrowing them is a genuine stroke risk factor. Seeing it on a screen before it causes harm sounds unarguably smart.
The USPSTF disagrees. It gave carotid screening of adults without symptoms a grade D in 2014 and reaffirmed it in 2021, concluding with moderate certainty that the harms outweigh the benefits. The American Academy of Family Physicians put the same advice on its Choosing Wisely list: “Don’t screen for carotid artery stenosis in asymptomatic adult patients.”
The reason is arithmetic, and it’s worth walking through because it’s counterintuitive.
The false-positive problem. In hospital vascular labs, compared with angiography, carotid ultrasound detects severe (70% or greater) narrowing with about 90% sensitivity and 94% specificity, according to the evidence review behind the USPSTF recommendation. That sounds excellent. But the USPSTF estimates severe carotid narrowing affects only about 0.5% to 1% of the general population. Here’s what happens when you screen 10,000 people and 1% of them have it:
| Actually has severe narrowing | Doesn’t | |
|---|---|---|
| People in this group | 100 | 9,900 |
| Ultrasound flags them (90% sensitivity / 6% false-positive rate) | 90 | 594 |
That’s 684 people told they may have a significant blockage, and only 90 of them, about 13%, actually do. Roughly seven in eight positive results are false alarms.
To be fair to Life Line: the people who show up at its events are older and more self-selected than the general population. In its own 3.6-million-person dataset, 3.9% had narrowing above a lower threshold of 50%. Even if you assume 4% of attendees have severe narrowing, which is generous, the same math gives you 360 true positives and 576 false ones. Most positives are still wrong.
Why false alarms matter here. A false positive on a mole check means a biopsy. On a carotid screen, the path can lead to confirmatory angiography, which carried a 0.4% to 1.2% stroke risk in the 2014 review, and potentially to surgery (carotid endarterectomy) or stenting. In the USPSTF’s 2021 review, 30-day stroke or death after endarterectomy ranged from 1.4% to 3.5% in national databases, and after stenting from 2.6% to 5.1% in Medicare data. When the test is meant to prevent strokes, a cascade that sometimes causes them is a serious problem.
Life Line’s counterargument. The company has argued that the USPSTF is evaluating screening as a path to surgery, whereas community screening is mostly meant to prompt lifestyle changes and medication. Some cardiologists agree that seeing plaque motivates patients and doctors to treat risk factors more aggressively. That’s a real point. But if your goal is to find out whether you have atherosclerosis so you can decide about a statin, there’s a better-studied test for that: a coronary artery calcium score, which measures plaque in the arteries that cause heart attacks, is built into cardiology guidelines for exactly this decision, and is used for people at intermediate risk.
What changed in 2025: the CREST-2 trial
This is the update most articles on Life Line haven’t caught up with, and it cuts somewhat in the company’s favor.
For years, the strongest argument against carotid screening was that there was little evidence that treating severe narrowing in people without symptoms beat good modern medical therapy. In November 2025, the New England Journal of Medicine published CREST-2, two parallel trials of about 2,500 people with severe (70%+) carotid narrowing and no symptoms. Everyone got intensive medical management (systolic blood pressure target below 130, LDL cholesterol target below 70 mg/dL, lifestyle coaching). Half also got a procedure.
- Stenting plus medical therapy: stroke or death over about four years fell from 6.0% to 2.8% compared with medical therapy alone. That’s a 3.2-point absolute reduction; about 31 people had to be treated to prevent one event.
- Surgery (endarterectomy) plus medical therapy: 3.7% versus 5.3%, a difference that was not statistically significant.
So if you genuinely have severe narrowing, there’s now trial evidence that a procedure, done by experienced operators, can help. That’s a meaningful shift. But keep three things in view:
- It doesn’t change the false-positive math above. CREST-2 enrolled people with confirmed severe narrowing, not people with a screening flag.
- Even without a procedure, the risk was low. With intensive medical therapy alone, the yearly rate of stroke on the narrowed side was about 1.7%. Most people in that group would never have had a stroke.
- The trial used vetted operators. Independent experts cautioned that less experienced centers may not match its complication rates, and one noted that adding or removing a handful of events would have erased the statistical significance.
The USPSTF hasn’t reconsidered carotid screening since CREST-2, and the task force itself has been in turmoil in 2026 (more on that below). Its grade D stands for now.
3. Peripheral arterial disease (ankle-brachial index): weak evidence, weak reassurance
The ankle-brachial index compares blood pressure at your ankles with blood pressure at your arms. A ratio below 0.9 suggests narrowed leg arteries, which signals higher heart attack and stroke risk.
The USPSTF rated ABI screening in adults without symptoms as grade I in 2018, meaning the evidence is insufficient to judge benefits against harms, and a 2024 surveillance check found nothing new to change that. No population trial has tested ABI screening on its own, and treatment trials in people without symptoms (aspirin, exercise) didn’t significantly reduce cardiovascular events or deaths.
The detail that matters most for you is buried in the evidence review. In the one fair-quality study comparing ABI with a reference standard (whole-body MR angiography in 306 Swedish 70-year-olds), the ABI had only 15% to 20% sensitivity. It caught very little of the disease that was there. When it was abnormal, it was usually right (99% specificity), but a normal result rules out much less than it seems to.
That’s the opposite of how most people experience a screening event. They walk out with a green “normal” and feel reassured. On this test, the reassurance is largely unearned.
4. Atrial fibrillation (one-time EKG): you probably already have a better screen on your wrist
Atrial fibrillation (AFib) is an irregular heart rhythm that raises stroke risk substantially, and it can be silent. Finding it matters because blood thinners lower that stroke risk.
The USPSTF’s 2022 recommendation for adults 50 and older without symptoms is grade I. The problem is that AFib often comes and goes, so a single snapshot misses most of it. In the trials the USPSTF reviewed, a one-time EKG found new AFib in just 0.6% more people than usual care, while longer monitoring (twice-weekly handheld EKGs, multi-week patches) found 2.8% to 4.8% more. And even the large STROKESTOP trial of repeated screening didn’t show a statistically significant reduction in stroke. Treatment isn’t free of harm either: anticoagulants raise the risk of major bleeding.
A short limb-lead EKG at a community event is the weakest version of a test that already lacks proof of benefit. A doctor checking your pulse, or a smartwatch with rhythm notifications, catches intermittent AFib over months rather than minutes. If you’re concerned about AFib because of palpitations or dizziness, that’s a symptom, and it needs a medical workup, not a screening package.
5. Bone density: not the test treatment decisions are based on
Osteoporosis screening has strong evidence. In January 2025 the USPSTF reaffirmed a grade B recommendation for women 65 and older and for postmenopausal women under 65 at increased risk, and found insufficient evidence (I) for men. That recommendation is built on DXA (also called DEXA), the low-dose X-ray that measures bone density at the hip and spine and is the basis for treatment decisions. (We covered how DXA works for body composition separately.)
Life Line’s bone density screening has historically used ultrasound instead: a heel ultrasound in its older materials, and from 2016 a device called Bindex that measures the shin bone and estimates hip density. Ultrasound can help flag who should get a DXA, but it doesn’t diagnose osteoporosis. If it flags you, you’ll still need a DXA. And Medicare covers DXA every 24 months for eligible people, including women 65 and older, at no cost when the provider accepts assignment.
6. The blood panels: real tests, nothing your doctor can’t order
The larger packages add finger-stick tests: cholesterol panel, glucose, A1C, hsCRP, liver and kidney markers, hormones. These are legitimate tests processed in a CLIA-certified lab. Cholesterol testing feeds statin decisions, and diabetes screening is a USPSTF grade B recommendation for adults 35 to 70 with overweight or obesity.
But there’s nothing here you can’t get through a routine checkup, usually covered as preventive care. Paying $100 to $300 extra makes sense mainly if you have no doctor and no insurance. One newer add-on, the p-tau217 “brain health” blood test, deserves a much more careful decision than a checkbox at a church hall. Our guide to Alzheimer’s blood tests without symptoms explains why.
Before paying for a screening package, check which tests are already guideline-recommended, and often fully covered, for your age and risk profile. Answer a few quick, non-identifying questions and get personalized eligibility guidance across all 6 categories ScanGlean covers. Take the Fit Check →
What Your $186 Actually Buys: The Odds From Life Line’s Own Data
The most useful numbers here come from Life Line itself. In the 2013 JACC analysis of more than 3.6 million self-referred people screened between 2003 and 2008:
- Carotid narrowing above 50%: 3.9%
- Peripheral artery disease (ABI below 0.9): 3.7%
- Abdominal aortic aneurysm (3 cm or larger): 0.9%
The rate of any of these rose steeply with age: about 2% in people in their 40s, 7.1% in their 60s, 13% in their 70s, and 22.3% in their 80s.
Read those numbers two ways. On one hand, most people walk out with nothing found, which is genuinely good news even if it means the money bought reassurance rather than a diagnosis. On the other, the conditions found most often (carotid narrowing and low ABI) are exactly the ones where evidence that screening improves outcomes is weakest or negative. The condition with the strongest evidence (AAA) is the rarest finding overall, because its risk is concentrated in older men who have smoked.
Why the Letter Works So Well
None of this means the people who go are being foolish. The pitch works because it speaks to something real, and it helps to see it clearly before you decide.
It turns a diffuse fear into a concrete action. Stroke is one of the most feared outcomes of aging, partly because it can take away independence rather than life. A letter that names that fear and offers a $150 way to act on it within weeks is giving you a sense of control. That feeling is valuable. It’s just separate from whether the test changes your odds.
It makes not going feel like the risky choice. Once you know a test exists, skipping it feels like negligence. Medicine has a name for the trap on the other side: a “normal” result feels like a clean bill of health, even from a test, like the ABI, that misses most disease.
It’s convenient, cheap-seeming, and social. No referral, no insurance paperwork, no waiting room, in a familiar local venue where your neighbors are going too. A price anchored as a discount off a higher “value” feels like a bargain, even when the most useful test in the bundle would be free elsewhere.
It doesn’t mention what happens after a positive. This is the main criticism physicians have made for over a decade. In a 2016 Memphis TV investigation of Life Line mailers, a local interventional cardiologist said the tests often produce false positives in people without symptoms, causing anxiety and labeling patients. The company responded that it runs quality control against hospital vascular labs and that no one has shown evidence of a large false-positive problem. Both statements can be true: a test can be accurately performed and still produce mostly false alarms when the condition is rare.
If you go, go with your eyes open. The question to hold on to isn’t “could this find something?” Almost any test can. It’s “if this finds something, what will I actually do differently, and is there evidence that helps?”
If Life Line Found Something: What to Do Next
If you’ve already been screened and your results letter flagged something, here’s a calm, practical path. In every case, step one is the same: book a visit with your primary care doctor and bring the report. Don’t start with a surgeon or proceduralist.
Carotid plaque or narrowing.
- Mild plaque is extremely common with age. It mostly means your cholesterol, blood pressure, smoking, and diabetes risk deserve attention. It’s a medication conversation, not a procedure conversation.
- Moderate or severe narrowing on a screening scan should be confirmed with a full carotid duplex ultrasound at an accredited vascular lab before anything else happens.
- Confirmed severe (70%+) narrowing without symptoms: intensive medical therapy is the foundation either way. After CREST-2, stenting at an experienced center is a reasonable option to discuss with a vascular specialist; routine surgery looks less compelling. Ask about the center’s own complication rates.
- Any symptoms (sudden weakness, numbness, speech trouble, or temporary vision loss in one eye) change everything. That’s an emergency, not a follow-up.
Abdominal aortic aneurysm. Size drives everything. Annual rupture risk is close to 0% at 3.0 to 3.9 cm, about 1% at 4.0 to 4.9 cm, and about 11% at 5.0 to 5.9 cm. Smaller aneurysms are monitored with periodic ultrasound, and repair is generally considered at 5.5 cm or larger, or with rapid growth. Stopping smoking is the most important thing you can control.
Low ankle-brachial index. Treat it as a cardiovascular risk signal. Expect a conversation about cholesterol, blood pressure, smoking, diabetes, and walking exercise, not an immediate leg procedure if you have no symptoms.
Possible atrial fibrillation. You’ll likely need a 12-lead EKG and possibly a longer monitor to confirm it. If it’s confirmed, the decision about blood thinners is based on a stroke-risk score (CHA₂DS₂-VASc) weighed against bleeding risk.
Low bone density estimate. Ask for a DXA scan, which is what treatment decisions are based on.
One practical note for anyone with a flag: follow-up testing ordered by your doctor is diagnostic, not screening, so it’s usually billed to insurance or Medicare under your normal cost-sharing, not free. That’s worth knowing before the cascade starts. Our guide to handling a full-body MRI finding covers the same dynamic for scans.
Who Life Line Screening Might Make Sense For
Being fair means saying where it fits, not just where it doesn’t.
- Men aged 65 to 75 who have ever smoked and have never had an aortic ultrasound. This is the strongest case. If you don’t have a doctor who’ll order the free Medicare version, a self-pay screen is a reasonable route to a test with real evidence.
- People with a parent or sibling who had an aortic aneurysm, who haven’t been screened.
- People with no regular doctor and no insurance, for whom a $150 to $190 bundle may be the most accessible check of blood pressure, cholesterol, and blood sugar. Even then, a community health center or pharmacy screening may be cheaper.
And who it’s not for: people under 50, women who have never smoked and have no family history of aneurysm (the AAA screen is grade D for them), anyone with symptoms that need a doctor, and anyone with a primary care doctor who’d rather spend the money on something with stronger evidence.
What to Do Instead
If the letter has made you think seriously about your stroke and heart risk, that’s a good outcome. Here’s the evidence-backed version of what it’s offering, most of it covered by insurance or Medicare:
- Know your blood pressure. High blood pressure is the largest modifiable stroke risk factor. Screening is a USPSTF grade A recommendation, and a validated home monitor costs less than the screening package.
- Get a cholesterol panel and a 10-year risk estimate from your doctor. Statin decisions are based on this.
- Check your blood sugar if you’re 35 to 70 and have overweight or obesity.
- If you’re a man 65 to 75 who has ever smoked, or have a family history of AAA, ask for the one-time aortic ultrasound.
- If you’re a woman 65 or older, or postmenopausal with risk factors, ask for a DXA.
- If your risk is borderline and a statin decision is genuinely uncertain, ask about a coronary artery calcium score. It’s usually self-pay ($100 to $200 at many centers) but directly informs treatment.
- If you have a smartwatch with rhythm notifications, turn them on. And take irregular-heartbeat alerts to a doctor.
For a broader view of which scans and clinics hold up, see our overview of preventive health scans and longevity clinics.
A Note on the USPSTF in 2026
This article leans on USPSTF grades, so it’s worth knowing the task force itself is in flux. It hasn’t met since March 2025. In May 2026, Health Secretary Robert F. Kennedy Jr. dismissed its two vice chairs, and in September 2026 he appointed eight new members, mostly specialists rather than the primary care and prevention experts who have traditionally made up the panel. For now, every existing recommendation cited here remains in effect, including the Affordable Care Act requirement that most plans cover A and B services without cost-sharing. The carotid, AAA, ABI, and AFib recommendations all predate CREST-2. We’ll update this article if any of them change.
The Bottom Line
Life Line Screening is a legitimate company selling real tests, and its staff, by most accounts, do them well. The problem isn’t how the tests are done. It’s which tests are in the bundle and who they’re sold to.
Of the four headline screenings, one (AAA) is strongly supported, but only for a specific group and is often free for them through Medicare. One (carotid) is advised against by the USPSTF and the AAFP for people without symptoms. Two (ABI and one-time EKG) lack evidence that screening helps, and one of those misses most of what it looks for. The 2025 CREST-2 results make a confirmed severe carotid blockage more treatable than before, which is genuinely new. But they don’t change the fact that most carotid flags in people without symptoms are false alarms.
If you’re a man between 65 and 75 who has smoked and you’ve never had your aorta checked, get it checked, at Life Line or through your doctor. For almost everyone else, the $186 is better spent on a home blood pressure monitor and a conversation with your doctor about the tests that are already recommended for you.
Frequently Asked Questions
Is Life Line Screening worth it?
For most people, mostly not, though one test is a real exception. The abdominal aortic aneurysm ultrasound is backed by randomized trials and a USPSTF grade B for men aged 65 to 75 who have ever smoked. The carotid artery ultrasound, which leads the package, is grade D (recommend against) for people without symptoms. The ankle-brachial index and one-time EKG for atrial fibrillation both have insufficient evidence (grade I). Many of the tests are available free through Medicare or insurance.
How much does Life Line Screening cost in 2026?
In October 2026 the four-test Heart & Stroke Risk package was listed at $186, with larger bundles at $285, $384, and $483 and a OneLife membership at $197 per year. Mailers and partner discounts through member organizations often bring the four-test package to roughly $129 to $159.
Does Medicare cover Life Line Screening?
No. Life Line is self-pay and says it doesn’t participate in Medicare, though packages are HSA/FSA eligible. Separately, Medicare Part B covers a one-time AAA ultrasound for at-risk people with a referral, and DXA bone density testing every 24 months for eligible people, both at no cost when the provider accepts assignment.
Why does the USPSTF recommend against carotid artery screening?
Because severe carotid narrowing is uncommon in people without symptoms, most positive results are false alarms, and the follow-up (confirmatory imaging, and sometimes surgery or stenting) can itself cause a stroke or death. The task force concluded with moderate certainty in 2021 that harms outweigh benefits for adults without symptoms.
Is Life Line Screening a scam?
No. It’s a legitimate company, operating since 1993, that uses real ultrasound and EKG equipment, has results reviewed by licensed physicians, and has published its data in peer-reviewed journals. Physicians’ criticism isn’t that the tests are fake. It’s that several are tests guideline bodies say shouldn’t be done in people without symptoms, and that the downsides aren’t explained.
What should I do if Life Line found a blockage in my carotid artery?
See your primary care doctor first and, for moderate or severe narrowing, get a confirmatory carotid duplex at an accredited vascular lab. Mild plaque mainly means treating cholesterol and blood pressure. For confirmed severe narrowing without symptoms, the 2025 CREST-2 trial found that stenting plus intensive medical therapy lowered four-year stroke or death from 6.0% to 2.8%, while surgery showed no significant benefit. It’s a specialist conversation, not an emergency, unless you have symptoms.
Is Life Line’s bone density test the same as a DEXA scan?
No. Life Line has historically used ultrasound at the heel or shin, which estimates bone density. DXA is the reference standard for diagnosing osteoporosis and guiding treatment, and Medicare covers it every 24 months for eligible people.
Who might actually benefit from Life Line Screening?
Mainly men aged 65 to 75 who have ever smoked and have never had an aortic ultrasound, especially without a regular doctor to order the free Medicare version, and people with a family history of aortic aneurysm.
This article is for general educational and informational purposes only. It is not medical advice, and it is not a substitute for diagnosis, treatment, or guidance from a licensed physician or other qualified healthcare provider. If you have symptoms of a stroke (sudden weakness or numbness, especially on one side; trouble speaking; vision loss; or severe headache), call 911. Pricing and package details were checked in October 2026 and can change; confirm directly with Life Line Screening before booking. Read our methodology for how we grade evidence.
Disclosure
ScanGlean does not sell screenings, scans, panels, or memberships, and we have no paid, affiliate, or referral relationship with Life Line Screening.
Sources
- US Preventive Services Task Force. Asymptomatic Carotid Artery Stenosis: Screening, final recommendation, February 2021.
- Krist AH, et al. (USPSTF). Screening for Asymptomatic Carotid Artery Stenosis: US Preventive Services Task Force Recommendation Statement. JAMA, 2021;325(5):476–481.
- US Preventive Services Task Force. Abdominal Aortic Aneurysm: Screening, final recommendation, December 2019.
- US Preventive Services Task Force. Peripheral Artery Disease and CVD: Screening With the Ankle-Brachial Index, final recommendation, July 2018.
- US Preventive Services Task Force. Atrial Fibrillation: Screening, final recommendation, January 2022.
- US Preventive Services Task Force. Osteoporosis to Prevent Fractures: Screening, final recommendation, January 2025.
- Brott TG, Meschia JF, et al. Medical Management and Revascularization for Asymptomatic Carotid Stenosis (CREST-2). New England Journal of Medicine, November 2025.
- TCTMD. Long-Awaited CREST-2 Results Bolster Stents for Asymptomatic Carotid Stenosis, November 2025.
- Savji N, Rockman CB, Skolnick AH, et al. Association between advanced age and vascular disease in different arterial territories: a population database of over 3.6 million subjects. Journal of the American College of Cardiology, 2013;61(16):1736–1743.
- American Academy of Family Physicians. Choosing Wisely: Screening for Carotid Artery Stenosis in Asymptomatic Adult Patients.
- Medicare.gov. Abdominal aortic aneurysm screenings, accessed October 2026.
- Medicare.gov. Bone mass measurements, accessed October 2026.
- Life Line Screening. Screening Services, accessed October 2026.
- Life Line Screening and Bone Index, Ltd. To Bring State-of-the-Art Bone Density Screening to American Communities, press release, 2016.
- Wise A. The truth behind that Life Line Screening letter in your mailbox. WMC Action News 5, June 16, 2016.
- MedCity News. Preventive Services Task Force gives incomplete picture of carotid artery screening, July 2012 (Life Line’s position).
- Bloomberg Law. RFK Jr. Fires Leaders of Preventative Services Advisory Panel, May 2026.
- STAT News. Kennedy names eight new members to USPSTF, September 17, 2026.